Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Ronald Fields

Critical Care Medicine Baton Rouge, LA Medical Doctor

NPI 1962498196 CMS profile 361048

7777 Hennessy Blvd Ste 701, Baton Rouge, LA 70808

Open in the dashboard

General payments

$10,866

527 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Ronald Fields of Baton Rouge, LA is reported in the CMS Open Payments database as having received $10,866 across 527 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 92nd percentile of Critical Care Medicine profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $2,858 139
2024 General $2,213 109
2023 General $2,269 98
2022 General $1,698 89
2021 General $400 14
2020 General $658 34
2019 General $770 44

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Ronald Fields
  • Critical Care Medicine median
  • Middle half of Critical Care Medicine
  • National median

In program year 2025, general payments to Ronald Fields were reported at $2,858. Among 2,664 Critical Care Medicine profiles paid that year, the median was $189 and the middle half received between $59 and $844.

Show as a table
Year Ronald Fields Critical Care Medicine median Middle half National median
2019 $770 $149 $51–$535 $163
2020 $658 $110 $30–$325 $114
2021 $400 $125 $34–$403 $132
2022 $1,698 $157 $49–$582 $149
2023 $2,269 $162 $56–$621 $160
2024 $2,213 $168 $53–$634 $164
2025 $2,858 $189 $59–$844 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. GlaxoSmithKline, LLC. $1,853 118 payments
  2. Boehringer Ingelheim Pharmaceuticals, Inc. $1,195 64 payments
  3. Genzyme Corporation $1,054 31 payments
  4. AstraZeneca Pharmaceuticals LP $886 48 payments
  5. Grifols USA, LLC $510 20 payments
  6. United Therapeutics Corporation $491 20 payments
  7. Actelion Pharmaceuticals US, Inc. $449 16 payments
  8. Regeneron Healthcare Solutions, Inc. $406 12 payments
  9. UCB, Inc. $353 21 payments
  10. Merck Sharp & Dohme Corporation $332 18 payments
  11. Other $3,338 159 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $10,642 524 payments
  2. Education $224 3 payments
Products named General payments · program years 2019–2025
  1. TRELEGY ELLIPTA $1,245 79 payments
  2. DUPIXENT $1,054 31 payments
  3. SPIRIVA RESPIMAT $738 44 payments
  4. Prolastin-C Liquid $510 20 payments
  5. NUCALA $427 33 payments
  6. OFEV Respiratory $413 18 payments
  7. UPTRAVI $403 14 payments
  8. TEZSPIRE $336 18 payments
  9. Briviact $301 18 payments
  10. OFEV Respiratory $301 15 payments
  11. Other $6,921 331 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 35 drugs

Part D claims

3,806

Median for Pulmonary Disease: 936

Drug cost

$1,982,850

Median for Pulmonary Disease: $487,987

Branded share of claims

84.9%

Median for Pulmonary Disease: 69.5%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Trelegy Ellipta Fluticasone/Umeclidin/Vilanter Brand 1,166 $939,991
Ofev Nintedanib Esylate Brand 20 $257,093
Uptravi Selexipag Brand 12 $172,499
Breztri Aerosphere Budesonide/Glycopyr/Formoterol Brand 97 $85,237
Spiriva Respimat Tiotropium Bromide Brand 110 $77,986
Breo Ellipta Fluticasone/Vilanterol Brand 159 $67,379
Dupixent Pen Dupilumab Brand 16 $60,122
Stiolto Respimat Tiotropium Br/Olodaterol Hcl Brand 86 $58,575
Spiriva Handihaler Tiotropium Bromide Brand 65 $49,068
Anoro Ellipta Umeclidinium Brm/Vilanterol Tr Brand 81 $39,184

The 10 drugs with the highest cost, of 35 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 9,233 Part D prescribers listed as Pulmonary Disease; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 18 billing codes

Paid by Medicare

$52,389

Medicare's payments for the services billed

Medicare patients

531

Average age 72

Services billed

1,697

296 women, 235 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
COPD 51%
Arthritis 51%
Ischemic heart disease 44%
Depression 34%
Diabetes 30%
Heart failure 28%
Chronic kidney disease 26%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 20 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
DUPIXENT
  • GENZYME CORPORATION $374
  • Regeneron Healthcare Solutions, Inc. $81
$455 16 —
TRELEGY ELLIPTA
  • GlaxoSmithKline, LLC. $240
$240 1,166 —
OFEV
  • Boehringer Ingelheim Pharmaceuticals, Inc. $201
$201 20 —
Prolastin-C Liquid
  • Grifols USA, LLC $171
$171 — —
TEZSPIRE
  • AstraZeneca Pharmaceuticals LP $142
$142 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 20 in the dashboard with a free account

Records

527 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Critical Care Medicine in Louisiana

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record